medigraphic.com

2023, Number 1

<< Back Next >>

Enf Infec Microbiol 2023; 43 (1)

Coronavirus, from the molecular to the clinical: a review

Roldán TMD, Cuartas AYS, Herrera AL, Castañeda PS, Coronado MG, Martínez SLM

Language: Spanish
References: 56
Page: 35-41
PDF size: 212.28 Kb.


ABSTRACT

Since the end of 2019, a significant increase infections due to SARS-COV-2 were detected around the world, and World Health Organization (WHO) declaring a pandemic. SARS-COV-2 generates a severe acute respiratory syndrome and affection to different organs due to the interaction between its four main proteins and the receptors of human cells through the angiotensin-converting enzyme 2 receptor. Comorbidities and some clinical characteristics has been described as risk factors to develop a severe infection. Although several diagnostic methods of this disease have been proposed, reverse transcriptase polymerase chain reaction (PCR) is recommended. Vaccines production has been difficult due to virus mutations, however, different vaccines has been approved and applied in many countries of the world.


REFERENCES

  1. Bonilla-Aldana, K., Villamil-Gómez, W.E., Rabaan, A.A.y Rodríguez-Morales, A., “Una nueva zoonosis viral depreocupación global: covid-19, enfermedad por coronavirus

  2. 2019”, Revista Médica de la Universidad de Antioquía,2020, 4 (1).2. Leguía, V.E., Niño, M.J. y Quino, F.M., “Coronavirus causantedel síndrome respiratorio de Oriente Medio (merscov)”,Revista Médica Carriónica, 2019; 1 (1): 1-15.

  3. Peiris, J.S.M., “Coronaviruses”, Medical Microbiology,2012: 587-593.

  4. Adhikari, S.P., Meng, S., Wu, Y.J., Mao, Y.P., Ye, R.X.,Wang, Q.Z. et al., “Epidemiology, causes, clinical manifestationand diagnosis, prevention and control ofcoronavirus disease (covid-19) during the early outbreakperiod: a scoping review”, Infect Dis Poverty, 2020, 9(1): 29.

  5. Báez-Santos, Y.M., St John, S.E. y Mesecar, A.D., “Thesars-coronavirus papain-like protease: structure, functionand inhibition by designed antiviral compounds”,Antiviral Res, 2015, 115: 21-38.

  6. Kaul, D., “An overview of coronaviruses including thesars-2 coronavirus: molecular biology, epidemiologyand clinical implications”, Curr Med Res Pract, 2020.

  7. World Health Organization (who), “Coronavirus disease2019 (covid-19) situation report 51”, Disponible en:https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200311-sitrep-51-covid-19.pdf?sfvrsn=1ba62e57_10.

  8. John Hopkins University of Medicine, United States,Coronavirus resource center. Disponible en: https://coronavirus.jhu.edu/map.html.

  9. Chan, J.F., Kok, K.H., Zhu, Z., Chu, H., To, K.K., Yuan,S. et al., “Genomic characterization of the 2019 novelhuman-pathogenic coronavirus isolated from a patientwith atypical pneumonia after visiting Wuhan”, EmergMicrobes Infect, 2020, 9 (1) :221-236.

  10. Li, F., “Structure, function, and evolution of coronavirusspike proteins”, Annu Rev Virol, 2016, 3 (1): 237-261.

  11. Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H. et al., “Genomiccharacterization and epidemiology of 2019 novelcoronavirus: implications for virus origins and receptorbinding”, Lancet, 2020, 395 (10224): 565-574.

  12. Rabaan, A.A., Al-Ahmed, S.H., Haque, S., Sah, R., Tiwari,R., Malik, Y.S. et al., “sars-cov-2, sars-cov, and mers-cov: acomparative overview”, Infez Med, 2020, 28 (2): 174-184.

  13. Schoeman, D. y Fielding, B.C., “Coronavirus envelopeprotein: current knowledge”, Virol J, 2019, 16 (1): 69.

  14. Kaul, D., “An overview of coronaviruses including thesars-2 coronavirus: molecular biology, epidemiologyand clinical implications”, Curr Med Res Pract, 2020.

  15. De Wilde, A.H., Snijder, E.J., Kikkert, M. y Van Hemert,M.J., “Host factors in coronavirus replication”, Curr TopMicrobiol Immunol, 2018, 419: 1-42.

  16. Shang, J., Wan, Y., Liu, C., Yount, B., Gully, K., Yang, Y. etal., “Structure of mouse coronavirus spike protein complexedwith receptor reveals mechanism for viral entry”,plos Pathog, 2020, 16 (3): e1008392.

  17. Song, Z., Xu, Y., Bao, L., Zhang, L., Yu, P., Qu, Y. et al.,“From sars to mers, thrusting coronaviruses into thespotlight”, Viruses, 2019, 11 (1): 59.

  18. Astuti, I. y Srafil, Y., “Severe acute respiratory syndromecoronavirus 2 (sars-cov-2): an overview of viral structureand host response”, Diabetes Metab Syndr, 2020, 14(4): 407-412.

  19. Walls, A.C., Park, Y.J., Tortorici, M.A., Wall, A., McGuire,A.T. y Veesler, D., “Structure, function, and antigenicityof the sars-cov-2 spike glycoprotein”, Cell, 2020, 181 (2):281-292.e6.

  20. Wan, Y., Shang, J., Graham, R., Baric, R.S. y Li, F., “Receptorrecognition by the novel coronavirus from Wuhan:an analysis based on decade-long structural studies ofsars coronavirus, J Virol, 2020, 94 (7): e00127-20.

  21. Zheng, Z., Peng, F., Xu, B., Zhao, J., Liu, H., Peng, J. etal., “Risk factors of critical and mortal covid-19 cases:a systematic literature review and meta-analysis”, J Infect,2020, S0163-4453(20)30234-6.

  22. Glowacka, I., Bertram, S., Herzog, P., Pfefferle, S.,Steffen, I., Muench, M.O. et al., “Differential downregulationof ace2 by the spike proteins of severe acuterespiratory syndrome coronavirus and human coronavirusnl63”, J Virol, 2010, 84 (2): 1198-1205.

  23. Castrucci, M.R., “Factors affecting immune responsesto the influenza vaccine”, Hum Vaccin Immunother,2018, 14 (3): 637-646.

  24. Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C.et al., “Pathological findings of covid-19 associated withacute respiratory distress syndrome”, Lancet RespirMed, 2020, 8 (4): 420-422.

  25. Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y.et al., “Epidemiological and clinical characteristics of 99cases of 2019 novel coronavirus pneumonia in Wuhan,China: a descriptive study”, Lancet, 2020, 395 (10223):507-513.

  26. Von der Thüsen, J. y Van der Eerden, M., “Histopathologyand genetic susceptibility in covid-19 pneumonia”,Eur J Clin Invest, 2020.

  27. Gandhi, R.T., Lynch, J.B. y Del Río, C., “Mild or moderatecovid-19”, N Engl J Med, 2020. doi: 10.1056/NEJMcp2009249.

  28. Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y. et al.,“Early transmission dynamics in Wuhan, China, of novelcoronavirus-infected pneumonia”, N Engl J Med, 2020,382 (13): 1199-1207.

  29. Tang, B., Wang, X., Li, Q., Bragazzi, N.L., Tang, S., Xiao,Y. et al., “Estimation of the transmission risk of the2019-ncov and its implication for public health interventions”,J Clin Med, 2020, 9 (2): 462.

  30. Kolifarhood, G., Aghaali, M., Mozafar Saadati, H., Taherpour,N., Rahimi, S., Izadi, N. et al., “Epidemiological andClinical aspects of covid-19: a narrative review”, ArchAcad Emerg Med, 2020, 8 (1): e41.

  31. Wei, W.E., Li, Z., Chiew, C.J., Yong, S.E., Toh, M.P. y Lee,V.J., “Presymptomatic transmission of sars-cov-2: Singapore,January 23-March 16, 2020”, mmwr Morb MortalWkly Rep, 2020, 69 (14): 411-415.

  32. Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J. etal., “Clinical characteristics of 138 hospitalized patientswith 2019 novel coronavirus-infected pneumonia in Wuhan,China”, jama, 2020, 323 (11): 1061-1069.

  33. Poyiadji, N., Shahin, G., Noujaim, D., Stone, M., Patel,S. y Griffith, B., “covid-19 associated acute hemorrhagicnecrotizing encephalopathy: ct and mri features”, Radiology,2020, 201187.

  34. Mao, L., Jin, H., Wang, M., Hu, Y., Chen, S., He, Q. et al.,“Neurological manifestations of hospitalized patientswith coronavirus disease 2019 in Wuhan, China”, jamaNeurol, 2020: e201127.

  35. Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H. et al., “Clinicalcourse and outcomes of critically ill patients withsars-cov-2 pneumonia in Wuhan, China: a single-centered,retrospective, observational study”, Lancet RespirMed, 2020, 8 (5): 475-481.

  36. Bonow, R.O., Fonarow, G.C., O’Hara, P.T. y Yancy, C.W,.“Association of coronavirus disease 2019 (covid-19) withmyocardial injury and mortality”, jama Cardiol, 2020.

  37. Inciardi, R.M., Lupi, L., Zaccone, G., Italia, L., Raffo, M.,Tomasoni, D. et al., “Cardiac involvement in a patient withcoronavirus disease 2019 (covid-19)”, jama Cardiol, 2020.

  38. Wu, P., Duan, F., Luo, C., Liu, Q., Qu, X., Liang, L. etal., “Characteristics of ocular findings of patients withcoronavirus disease 2019 (covid-19) in Hubei Province,China”, jama Ophthalmol, 2020: e201291.

  39. Vetter, P., Vu, D.L., L’Huillier, A.G., Schibler, M., Kaiser,L. y Jacquerioz, F., “Clinical features of covid-19”, bmj,2020, 369: m1470.

  40. Giacomelli, A., Pezzati, L., Conti, F., Bernacchia, D.,Siano, M., Oreni, L. et al., “Self-reported olfactory andtaste disorders in sars-cov-2 patients: a cross-sectionalstudy”, Clin Infect Dis, 2020: ciaa330.

  41. Liu, Y., Yan, L.M., Wan, L., Xiang, T.X., Le, A., Liu, J.M.et al., “Viral dynamics in mild and severe cases of covid-19”, Lancet Infect Dis, 2020: S1473-3099(20)30232-2.

  42. Liu, K., Fang, Y.Y., Deng, Y., Liu, W., Wang, M.F., Ma, J.P.et al., “Clinical characteristics of novel coronavirus casesin tertiary hospitals in Hubei Province”, Chin Med J(Inglaterra), 2020, 133 (9): 1025-1031.

  43. Wu, C., Chen, X., Cai, Y., Xia, J., Zhou, X., Xu, S. et al.,“Risk factors associated with acute respiratory distresssyndrome and death in patients with coronavirus disease2019 pneumonia in Wuhan, China”, jama Intern Med,2020: E200994.

  44. Wu, Z. y McGoogan, J.M., “Characteristics of and importantlessons from the coronavirus disease 2019 (covid-19) outbreak in China: summary of a report of 72 314cases from the Chinese Center for Disease Control andPrevention”, jama, 2020.

  45. Dai, M., Liu, D., Liu, M., Zhou, F., Li, G., Chen, Z. et al.,“Patients with cancer appear more vulnerable to sarscov-2: a multi-center study during the covid-19 outbreak”,Cancer Discov, 2020: cd-20-0422.

  46. Márquez-González, H., Méndez-Galván, J.F., Reyes-López, A., Klünder-Klünder, M., Jiménez-Juárez, R.,Garduño-Espinosa, J. y Solórzano-Santos, F., “Coronavirusdisease-2019 survival in Mexico: a cohort study onthe interaction of the associated factors”, Front PublicHealth, 2021, 9: 660114.

  47. Cevik, M., Bamford, C. y Ho, A., “covid-19 pandemic:a focused review for clinicians”, Clin Microbiol Infect,2020: S1198-743X(20)30231-7.

  48. Ng, L.F.P. y Hiscox, J.A., “Coronaviruses in animals andhumans”, bmj, 2020, 368: m634.

  49. Centros de Control y Prevención de Enfermedades,“Enfermedad por coronavirus 2019 (covid-19): gruposcon mayor riesgo de enfermedad grave. Disponible en:https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/groups-at-higher-risk.html.

  50. Pabla, S. y Pabla, S., “Real-time polymerase chain reaction”,Resonance, 2008, 13 (4): 369-377.

  51. Patel, R., Babady, E., Theel, E.S., Storch, G.A., Pinsky,B.A., St George, K. et al., “Report from the American Societyfor Microbiology covid-19 International Summit, 23March 2020: Value of diagnostic testing for sars-cov-2/covid-19”, mBio, 2020, 11 (2): e00722-720.

  52. Yu, F., Du, L., Ojcius, D.M., Pan, C. y Jiang, S., “Measuresfor diagnosing and treating infections by a novelcoronavirus responsible for a pneumonia outbreak originatingin Wuhan, China”, Microbes Infect, 2020, 22 (2):74-79. doi: 10.1016/j.micinf.2020.01.003.

  53. Loeffelholz, M.J. y Tang, Y.W., “Laboratory diagnosis ofemerging human coronavirus infections: the state ofthe art”, Emerg Microbes Infect, 2020, 9 (1): 747-756.

  54. Zhang, W., Du, R.H., Li, B., Zheng, X.S., Yang, X.L., Hu,B. et al., “Molecular and serological investigation of2019-ncov infected patients: implication of multipleshedding routes”, Emerg Microbes Infect, 2020, 9 (1):386-389.

  55. Ahn, D.G., Shin, H.J., Kim, M.H., Lee, S., Kim, H.S.,Myoung, J. et al., “Current status of epidemiology, diagnosis,therapeutics, and vaccines for novel coronavirusdisease 2019 (covid-19)”, J Microbiol Biotechnol, 2020,30 (3): 313-324.

  56. Zhang, J., Yang, W., Huang, F. y Zhang, K., “Effectivenessof mrnA and viral-vector vaccines in epidemic periodled by different sars-cov-2 variants: a systematic reviewand meta-analysis”, J Med Virol, 2023. doi: 10.1002/jmv.28623. Epub disponible.




2020     |     www.medigraphic.com